Have a website account?
for exclusive website content.
Advisory Committee Board
Submit Multimedia Files
Conflict of Interest
Human and Animal Rights
AME Editing Service
Peer Review Process
Focused Issues (Published)
Focused Issues (Ongoing)
Article Processing Charges
Publish Ahead of Print
Publish Ahead of Print
Metabolic profiles of serum samples from ground glass opacity represent potential diagnostic biomarkers for lung cancer
Jian-Zhong Li, Yuan-Yang Lai, Jian-Yong Sun, Li-Na Guan, Hong-Fei Zhang, Chen Yang, Yue-Feng Ma, Tao Liu, Wen Zhao, Xiao-Long Yan, Shao-Min Li
Influence and mechanism of lung cavitation development on antiangiogenic therapy
Man Jiang, Chuantao Zhang, Dong Liu, Yongjie Wang, Hongmei Wang, Tianjun Li, Helei Hou, Na Zhou, Jingjuan Zhu, Hongying Lv, Chuanyu Zhang, Bingliang Fang, Xiaochun Zhang
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
Alex Martinez-Marti, Alejandro Navarro, Enriqueta Felip
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?
Eric G. Nesbit, Ticiana A. Leal, Tim J. Kruser
Strengths and limitations of large databases in lung cancer radiation oncology research
Vikram Jairam, Henry S. Park
Brain metastases in oncogene-driven non-small cell lung cancer
Makoto Nishino, Kenzo Soejima, Tetsuya Mitsudomi
Recent developments in limited stage small cell lung cancer
Kristin A. Higgins, Sophia Gorgens, Lisa J. Sudmeier, Corinne Faivre-Finn
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Natalie M. Andrews Wright, Glenwood D. Goss
Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions
Hongqing Zhuang, Siyu Shi, Joe Y. Chang
Proton therapy for non-small cell lung cancer: the road ahead
Eric D. Brooks, Matthew S. Ning, Vivek Verma, X. Ronald Zhu, Joe Y. Chang
Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer
Fabrizio Tabbò, Silvia Novello
Changing equipoise in the landscape of radiation for oligometastatic lung cancer
Samuel R. Schroeder, Michael Leenders, Puneeth Iyengar, Dirk de Ruysscher
The first attempt worldwide to test PD-1 antibody on multiple “Stage 0” lung cancer
Erratum: Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine
Sensitive molecular testing methods can demonstrate NSCLC driver mutations in malignant pleural effusion despite nonmalignant cytology
Daniel P. Steinfort, Sevastjan Kranz, Anthony Dowers, Leakhena Leas, Voula Dimitriadis, Kym Pham, Arthur Hsu, Steven Bozinovski, Louis B. Irving, Paula Loveland, Michael Christie
Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management
Yayi He, Caicun Zhou
Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain
Jose M. Pacheco, Drew Moghanaki
Osimertinib in first line setting: for Asian patients
Keisuke Onoi, Yoshiko Kaneko, Junji Uchino
Measuring tumor mutation burden in cell-free DNA: advantages and limits
Alfredo Addeo, Glen J. Weiss
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)
Greg Durm, Nasser Hanna
Sex disparities in lung cancer incidence: validation of a long-observed trend
Jessica A. Hellyer, Manali I. Patel
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?
Francesco Passiglia, Paolo Bironzo, Giorgio V. Scagliotti
Is the game over for PD-1 inhibitors in
mutant non-small cell lung cancer?
Maria A. Velez, Timothy F. Burns
Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
Rui Li, Steven M. Dubinett
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Jose M. Pacheco
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?
Yiqing Huang, Robert J. Walsh, Ross A. Soo
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Biagio Ricciuti, Giuseppe Lamberti, Fausto Roila, Giulio Metro
Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors
Jyoti Malhotra, Salma K. Jabbour, Sharon Pine
Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more
Angel Moran, Megan E. Daly
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
Laura Le, Ritchell van Dams, Percy Lee
Improving outcomes for brain metastases in EGFR mutated NSCLC
Jennifer W. Carlisle, Suresh S. Ramalingam
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Andrew J. Piper, Kartik Sehgal, Daniel B. Costa, Deepa Rangachari
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
Alice Mogenet, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery
Tamar B. Nobel, Prasad S. Adusumilli, Daniela Molena
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Debora Bruno, Afshin Dowlati
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
Antonio Passaro, Filippo de Marinis
Erlotinib as standard adjuvant therapy for resectable
mutation-positive non-small cell lung cancer
Satomi Tanaka, Junji Uchino
Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
Maria Jove, Noelia Vilariño, Ernest Nadal
Can liquid biopsy-guided
-targeted therapy be a surrogate for the tissue-based standard approach?
The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer
Carme Obiols, Sergi Call, Ramon Rami-Porta
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Amy Lauren Cummings, Edward B. Garon